Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approv...

Full description

Bibliographic Details
Main Authors:	Jingyi Wang, Xiaoqing Li, Juan Zhou, Dan Qiu, Mengyao Zhang, Lan Sun, Shengwen Calvin Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer anti-angiogenesis therapy front-line treatment elderly patients case report Anlotinib hydrochloride
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/full

Similar Items

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
by: Chongya Zhai, et al.
Published: (2021-02-01)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
by: Shasha Wang, et al.
Published: (2022-05-01)

Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer
by: WANG Wei, et al.
Published: (2020-11-01)

Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib
by: Liling HUANG, et al.
Published: (2021-10-01)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
by: Nanlin Hu, et al.
Published: (2021-08-01)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
by: Yingbo Shao, et al.
Published: (2022-07-01)

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
by: Min Yan, et al.
Published: (2024-03-01)

A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
by: Yang H, et al.
Published: (2021-11-01)

Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
by: Song PF, et al.
Published: (2020-11-01)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
by: Caiyun Nie, et al.
Published: (2022-07-01)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
by: Yuying Gan, et al.
Published: (2021-11-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
by: Ying Cheng, et al.
Published: (2020-04-01)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
by: Di Wu, et al.
Published: (2019-07-01)

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
by: Jiaxuan Liu, et al.
Published: (2025-01-01)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
by: Nan Jin, et al.
Published: (2022-04-01)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by: Jingzhen Shi, et al.
Published: (2020-07-01)

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
by: Lijun Liang, et al.
Published: (2019-02-01)

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
by: Jiang HT, et al.
Published: (2021-11-01)

Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
by: Qin Gao, et al.
Published: (2020-01-01)

Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
by: ZHANG Xiaojuan, et al.
Published: (2023-06-01)

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
by: Li S, et al.
Published: (2023-11-01)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
by: Zhujun Liu, et al.
Published: (2022-05-01)

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial
by: Hui Zhu, MD, et al.
Published: (2022-06-01)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
by: Jia-Yi Huang, et al.
Published: (2023-04-01)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2021-10-01)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
by: Jia Li, et al.
Published: (2022-06-01)

Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
by: Pengbo Deng, et al.
Published: (2022-10-01)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2022-01-01)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
by: Lina Tang, et al.
Published: (2022-05-01)

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
by: Cheng JD, et al.
Published: (2020-07-01)

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
by: Yue Liu, et al.
Published: (2022-05-01)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
by: Yanhua Yue, et al.
Published: (2022-08-01)

Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial
by: Shuzhen Lai, et al.
Published: (2024-05-01)

Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study
by: Ying Cheng, et al.
Published: (2023-06-01)

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
by: Shujing Shen, et al.
Published: (2024-07-01)

Anlotinib induced ferroptosis through the p53/xCT/GPX4 pathway in non-small cell lung cancer
by: Zhansheng Jiang, et al.
Published: (2025-03-01)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Bushu Xu, et al.
Published: (2023-10-01)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
by: Xiaohua Zhang, et al.
Published: (2020-06-01)